Google
Trusted Resources: News & Events
Latest announcements and gatherings
Claudia Morris, MD, Uncovers Potential New Mechanism of Action for Hydroxyurea
Data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition showed the benefits of using Arginine (Arg) to supplement treatment of vaso-occlusive episdes (VOEs) in patients with sickle cell disease (SCD). While statistically insignificant, they observed a clinically relevant decrease in total parenteral opioid (TPO) and a shortened time to crisis resolution in both intervention groups treated with Arg compared with placebo.
In an interview with HCPLive, lead investigator and presenter Claudia Morris, MD, Childrens Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, shared a novel discovery found during the investigation that hadn’t been addressed in her talk at the conference.
“In our mitochondrial work, we actually uncovered a potential new mechanism of action (MOA) for hydroxyurea,” she explained, “because we saw that the patients who were on hydroxyurea had improved mitochondrial function and lower oxidative stress than the patients who are not on the hydroxyurea.”
+myBinderRelated Content
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Melissa Claar, MA, RN, CPNPNurse Practitioner Melissa Claar, MA, RN...
-
Orphan Drugs for Sickle Vaso-occlusion: Dawn of a New Era of Targeted TreatmentWhile an orphan disease in the USA, sick...
-
Annual management of Sickle cell disease conference 2018The Sickle Cell Disease Associat...
-
The clinical presentation, utilization, and outcome of individuals with sickle cell anaemia presenting to urban emer...Background: Sickle cell anaemia (SCA) i...
-
Robert Molokie, MDDr. Robert Molokie is a hematologist and...
-
The 2020 ASPHO Conference – CANCELEDMore than 1,200 pediatric hematology/onc...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.